.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,453,446

« Back to Dashboard

Claims for Patent: 5,453,446

Title: Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Abstract:R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
Inventor(s): Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:08/255,046
Patent Claims: 1. A method of treating a subject for Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the subject.

2. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered orally.

3. The method of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit.

4. The method of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit.

5. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered rectally.

6. The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit.

7. The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit.

8. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered transdermally.

9. The method of claim 8, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit.

10. The method of claim 8, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit.

11. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered parenterally.

12. The method of claim 11, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 1 to 10 mg per mL per daily dosage unit.

13. The method of claim 12, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 5 mg per mL per daily dosage unit.

14. The method of claim 13 which further comprises administering to the subject a decarboxylase inhibitor in an amount effective to ensure L-Dopa uptake.

15. The method of claim 14, wherein the decarboxylase inhibitor is Carbidopa.

16. The method of claim 15, wherein the decarboxylase inhibitor is benserazide.

17. The method of claim 1 which further comprises administering to the subject Levodopa in an amount relative to the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the disease.

18. The method of claim 1 which further comprises administering to the subject a decarboxylase inhibitor in an amount effective to ensure L-Dopa uptake.

19. The method of claim 18, wherein the decarboxylase inhibitor is Carbidopa.

20. The method of claim 18, wherein the decarboxylase inhibitor is benserazide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc